|
|
Systemic Lupus Erythematosus: The Wait For Lupus-Specific TreatmentsPublished by: Datamonitor Published: May. 30, 2003 - 43 Pages Table of Contents EXECUTIVE SUMMARY AN INTRODUCTION TO LUPUS LUPUS TREATMENT LUPUS PIPELINE APPENDIX AbstractIntroduction:Systemic lupus erythematosus (SLE) has received increased attention over the past several years due to a higher prevalence than previously thought and an influx of pipeline drugs with lupus-specific indications. These drugs, in addition to increased patient and physician awareness, are set to greatly improve treatment outcomes for patients with SLE, a largely underserved population. Scope: * Introduction to the current state of SLE and its potential causes, symptoms and current treatments * In-depth examination of SLE epidemiology, defining the patient populations in the seven major markets through analysis of numerous studies * Clinical update and analysis of six pipeline drugs seeking approval for lupus indications Report Highlights: Decades have passed since the last drug was developed that truly changed the face of lupus treatment. The six promising drugs in clinical development for lupus will vastly improve treatment outcomes for patients and increase the size of the lupus market value, which at this point is highly genericized. The high level of unmet need offers a sizable market advantage to the first company able to gain FDA approval for a SLE treatment. However, studies showing an improvement in efficacy and safety over immunosuppressants are required for premium pricing. Reasons to Purchase: * Gain a greater understanding of the size of the SLE population in the seven major markets * Identify unmet needs in SLE, from diagnosis to treatment, for more focused research * Evaluate potential pipeline candidates for the treatment of SLE and related conditions, with a focus on identifying licensing opportunities Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||